Yourgene Health PLC (LON:YGEN) announced that its Yourgene Genomic Services has been added to the UK government’s approved coronavirus (COVID-19) private testing providers list.
The list is for the Test to Release for International Travel scheme introduced on December 15, 2020, and also for general coronavirus testing.
The AIM-listed firm added that it has conducted in-silico analysis studies for the new virus strain which suggests that the performance of the assay will remain the same.
The Test to Release scheme is a programme designed to reduce quarantine periods for travellers arriving in the UK: passengers can pay for a COVID-19 test through the list of approved private providers to halve the two-week mandatory isolation period.
Yourgene said its service has the full COVID-19 testing service offering required to meet the Department of Health & Social Care’s 15 minimum standards and it will go live with the Test to Release scheme in early January 2021 though the general coronavirus testing offering is already available.
“We are extremely pleased to be an approved private provider for the Test to Release scheme to support international travel to the UK, as well as more general UK COVID-19 testing,” said chief executive Lyn Rees in a statement.
“This approval confirms the high standards and service levels we have been setting for our COVID-19 testing partners and in our wider Genomic Services laboratory offering.”
Shares rose 6% to 15.57p on Thursday morning.